Beaufort F, Fereberger W
Wien Med Wochenschr. 1983 Apr 15;133(7):169-73.
38 patients with metastasizing breast cancer who were stratified according to prognostic criteria were treated with high-dose medroxyprogesterone acetate (MPA). The response rate in our series was nearly 50 percent. The indication for high-dose gestagen therapy as well as anti-tumor activity and side effects are discussed by comparing our results with recent communications in the literature.